1 Qstrowski MJ.An assessment of thelong-Term results of controlling the reaccumulation of malignant effusions usingintracavity bleomycin [J]. Cancer,1986,57:721-727.
7WU Hai-ying GUAN Zhong-zhen(Cancer Hospital, Sun Y at-sen University of Medical Sciences,Guan gzhou 510060).白介素－2的Ⅱ期临床试验报告[J].癌症,1994,13(3):221-228. 被引量：30
6Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions[J]. Chest, 2000, 117 (1):79 -86.
7Heffner JE, Klein JS. Recent advance in the diagnosis and management of malignant pleural effusions[J]. Mayo Clin Proc, 2008, 83(2): 235 - 250.
8Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non- small cell lung cancer[J]. Chest, 2004, 126(5): 1 529- 1 539.
9Tikhonov I, Moiz K, Wallance M, et al. Staphylococcal superantigens induce lymphotactin production by human CD4^+ and CD8^+ T-cells[J]. Cytokine, 2001, 16(2): 73 - 78.
10Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions[J]. Thorax, 2003, 58 (suppl 2) : ii29 - ii38.
